Financial Performance Projections - The estimated net profit for 2024 is projected to be a loss of between 190 million and 240 million CNY, representing a decline of 123% to 182% compared to the previous year's loss of 85.08 million CNY[2]. - The net profit after deducting non-recurring gains and losses is expected to be a loss of between 184 million and 243 million CNY, which is an improvement of 44% to 57% from the previous year's loss of 432.69 million CNY[2]. - The basic earnings per share are projected to be a loss of between 0.6389 CNY and 0.8071 CNY, compared to a loss of 0.2806 CNY in the previous year[2]. Fair Value and Impairment - The fair value change is expected to negatively impact the net profit attributable to shareholders by approximately 30 million to 15 million CNY in 2024, contrasting with a positive impact of 331 million CNY in 2023[5]. - The goodwill impairment for the consolidated financial statements is anticipated to be between 55 million and 80 million CNY in 2024, a decrease from the 248 million CNY impairment in 2023[5]. Business Segments and Operations - The digital security and confidentiality segment is expected to show a reduction in losses in 2024[5]. - The company is currently involved in arbitration regarding performance compensation obligations from shareholders related to the acquisition of a 78.33% stake in Wanlihong Technology Co., Ltd.[6]. - The company has not yet received performance compensation from 14 parties related to the 2022 and 2023 performance commitments, and is actively pursuing this matter[6]. Investor Guidance - The financial data for 2024 will be finalized and disclosed in the company's annual report[8]. - Investors are advised to pay attention to investment risks and monitor company announcements[7].
东方中科(002819) - 2024 Q4 - 年度业绩预告